Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865228 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
NCT00865228: Clinical Trial Phase 2 study, sponsored by Takeda.
NCT00865228 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 224 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00865228, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.
Interventions
- DRUG Placebo
- DRUG Lapaquistat acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2007-07 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Why NCT00865228 stopped before completion
NCT00865228 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00865228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00865228 about?
NCT00865228 is a clinical study titled "Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia". The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.
What is the current status of trial NCT00865228?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2007-07. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00865228?
The interventions under investigation include: Placebo (DRUG), Lapaquistat acetate (DRUG).
Who is sponsoring clinical trial NCT00865228?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00865228's enrollment target sits among peer trials
224 269th of 2000 higher than 1,727 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia